These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 1342678

  • 21. Serotonin receptors: subtypes, functional responses and therapeutic relevance.
    Saxena PR.
    Pharmacol Ther; 1995 May; 66(2):339-68. PubMed ID: 7667401
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Contribution of serotonin neurotoxins to understanding psychiatric disorders: the role of 5-HT2 receptors in schizophrenia and antipsychotic activity.
    Schmidt CJ, Kehne JH, Carr AA, Fadayel GM, Humphreys TM, Kettler HJ, McCloskey TC, Padich RA, Taylor VL, Sorensen SM.
    Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():25-32. PubMed ID: 7911139
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists.
    Holsboer F, Ising M.
    Eur J Pharmacol; 2008 Apr 07; 583(2-3):350-7. PubMed ID: 18272149
    [Abstract] [Full Text] [Related]

  • 26. Therapeutic potential of serotonin antagonists in depressive disorders.
    Wood MD, Thomas DR, Watson JM.
    Expert Opin Investig Drugs; 2002 Apr 07; 11(4):457-67. PubMed ID: 11922855
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Neuropeptides: relevance in treatment of depression and anxiety disorders.
    Madaan V, Wilson DR.
    Drug News Perspect; 2009 Apr 07; 22(6):319-24. PubMed ID: 19771321
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Receptor alterations associated with serotonergic agents: an autoradiographic analysis.
    Wamsley JK, Byerley WF, McCabe RT, McConnell EJ, Dawson TM, Grosser BI.
    J Clin Psychiatry; 1987 Mar 07; 48 Suppl():19-25. PubMed ID: 3029045
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Pharmacology of serotonin uptake inhibitors: focus on fluvoxamine.
    Hrdina PD.
    J Psychiatry Neurosci; 1991 Jul 07; 16(2 Suppl 1):10-8. PubMed ID: 1931931
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. L-5-hydroxytryptophan in depression and anxiety.
    van Praag HM, Kahn RS.
    Schweiz Rundsch Med Prax; 1988 Aug 23; 77(34A):40-6. PubMed ID: 3055148
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.